<?xml version="1.0" encoding="UTF-8"?>
<ref id="R27">
 <label>27</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Redelman-Sidi</surname>
    <given-names>G</given-names>
   </name>, 
   <name name-style="western">
    <surname>Michielin</surname>
    <given-names>O</given-names>
   </name>, 
   <name name-style="western">
    <surname>Cervera</surname>
    <given-names>C</given-names>
   </name>, 
   <etal>et al</etal>
  </person-group>
  <article-title>Escmid Study Group for infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors)</article-title>. 
  <source>Clin Microbiol Infect</source>
  <year>2018</year>;
  <volume>24 Suppl 2</volume>:
  <fpage>S95</fpage>â€“
  <lpage>107</lpage>. 
  <pub-id pub-id-type="doi">10.1016/j.cmi.2018.01.030</pub-id>
  <?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/29427804?>
  <pub-id pub-id-type="pmid">29427804</pub-id>
 </mixed-citation>
</ref>
